Insulet Corp. (PODD)PODDInsulet Corp.

Income Statement

Revenue, expenses, and profitability analysis

Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Revenue	2.901B	761.700M	783.800M	706.300M	649.100M	569.000M	597.500M	543.900M	488.500M
Cost of Goods Sold	840.900M	232.600M	215.200M	196.200M	196.900M	160.000M	166.600M	166.800M	157.600M
Gross Profit	2.060B	529.100M	568.600M	510.100M	452.200M	409.000M	430.900M	377.100M	330.900M
Gross Profit Margin	69.5%	69.5%	72.5%	72.2%	69.7%	71.9%	72.1%	69.3%	67.7%
Total Operating Expenses	1.553B	406.900M	422.300M	392.400M	331.100M	320.200M	321.600M	289.000M	276.400M
Research & Development	331.200M	89.700M	90.900M	77.200M	73.400M	59.600M	60.600M	54.900M	53.900M
Selling, General & Administrative	1.222B	317.200M	331.400M	315.200M	257.700M	260.600M	261.000M	234.100M	222.500M
Operating Income (EBIT)	507.200M	122.100M	146.300M	117.700M	121.100M	88.800M	109.300M	88.100M	54.500M
Operating Margin	16.0%	16.0%	18.7%	16.7%	18.7%	15.6%	18.3%	16.2%	11.2%
Income Before Tax (EBT)	404.400M	113.000M	140.200M	122.800M	28.400M	48.100M	111.300M	82.900M	51.100M
Interest Income	29.300M	4.900M	5.700M	8.600M	10.100M	10.300M	10.300M	10.500M	9.300M
Interest Expense	69.500M	14.700M	19.600M	15.600M	19.600M	9.200M	8.700M	12.300M	11.000M
Other Income/Expense	-102.800M	-9.100M	-6.100M	5.100M	-92.700M	-40.700M	2.000M	-5.200M	-3.400M
Net Income	302.800M	91.100M	101.600M	87.600M	22.500M	35.400M	100.700M	77.500M	188.600M
Income Tax Expense	101.500M	21.900M	38.500M	35.200M	5.900M	12.700M	10.600M	5.400M	-137.500M
Net Profit Margin	12.0%	12.0%	13.0%	12.4%	3.5%	6.2%	16.9%	14.2%	38.6%
EBITDA	575.000M	153.900M	190.400M	160.400M	70.300M	79.000M	141.500M	116.500M	81.300M
EBITDA Margin	20.2%	20.2%	24.3%	22.7%	10.8%	13.9%	23.7%	21.4%	16.6%
Depreciation & Amortization	101.100M	26.200M	30.600M	22.000M	22.300M	21.700M	21.500M	21.300M	19.200M
EPS Basic	4.31	1.30	1.45	1.24	0.32	0.50	1.44	1.11	2.69
EPS Diluted	4.30	1.30	1.44	1.24	0.32	0.50	1.39	1.08	2.59
Shares Outstanding	69.986M	69.986M	70.364M	70.645M	70.330M	70.272M	70.164M	70.123M	70.062M
Diluted Shares Outstanding	70.202M	70.202M	70.667M	70.661M	70.641M	74.111M	74.079M	73.951M	73.802M

Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.708B	2.072B	1.697B	1.305B	1.099B	904.400M	738.200M	563.823M
Cost of Goods Sold	768.200M	625.900M	537.200M	499.700M	346.700M	322.100M	257.900M	193.655M
Gross Profit	1.940B	1.446B	1.160B	805.600M	752.100M	582.300M	480.300M	370.168M
Gross Profit Margin	71.6%	69.8%	68.3%	61.7%	68.4%	64.4%	65.1%	65.7%
Total Operating Expenses	1.466B	1.137B	939.900M	768.000M	626.100M	530.800M	430.300M	342.800M
Research & Development	301.100M	219.600M	205.000M	180.200M	160.100M	146.800M	132.300M	88.606M
Selling, General & Administrative	1.165B	917.200M	734.900M	587.800M	466.000M	384.000M	298.000M	248.000M
Operating Income (EBIT)	473.800M	308.900M	220.000M	37.600M	126.000M	51.500M	50.000M	27.400M
Operating Margin	17.5%	14.9%	13.0%	2.9%	11.5%	5.7%	6.8%	4.9%
Income Before Tax (EBT)	339.500M	300.200M	214.600M	9.800M	20.500M	9.700M	14.500M	5.200M
Interest Income	34.700M	39.500M	28.600M	9.300M	500K	3.000M	—	6.705M
Interest Expense	79.700M	42.700M	36.200M	36.000M	61.700M	48.100M	34.600M	22.197M
Other Income/Expense	-134.300M	-8.700M	-5.400M	-27.800M	-105.500M	-41.800M	-35.500M	-22.200M
Net Income	247.100M	418.300M	206.300M	4.600M	16.800M	6.800M	11.600M	3.292M
Income Tax Expense	92.400M	-118.100M	8.300M	5.200M	3.700M	2.900M	2.900M	1.900M
Net Profit Margin	9.1%	20.2%	12.2%	0.4%	1.5%	0.8%	1.6%	0.6%
EBITDA	532.300M	423.700M	323.600M	109.000M	139.600M	110.300M	74.200M	47.100M
EBITDA Margin	19.7%	20.5%	19.1%	8.4%	12.7%	12.2%	10.1%	8.4%
Depreciation & Amortization	113.100M	80.800M	72.800M	63.200M	57.400M	55.400M	27.900M	15.600M
EPS Basic	3.51	5.97	2.96	0.07	0.25	0.11	0.19	0.06
EPS Diluted	3.48	5.78	2.94	0.07	0.25	0.10	0.19	0.05
Shares Outstanding	70.348M	70.076M	69.751M	69.375M	67.698M	64.735M	60.594M	58.860M
Diluted Shares Outstanding	71.886M	73.890M	73.633M	69.910M	68.579M	65.946M	62.304M	61.008M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA

5,400 employees

www.insulet.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Ashley A. McEvoy

View full financials